April 30, 2026 — A sharp rise in platinum prices is threatening the manufacturing viability of three essential chemotherapy drugs — cisplatin, carboplatin, and oxaliplatin — pushing global oncology drug shortages to their worst levels since 2019. Indian manufacturers have formally approached the National Pharmaceutical Pricing Authority (NPPA) seeking a 50% increase in maximum retail price ceilings, warning that continued production will become financially unsustainable.
Cisplatin, carboplatin, and oxaliplatin are platinum coordination complexes whose synthesis depends directly on refined platinum. Unlike most small-molecule drugs, platinum-group metals account for 30–50% of API production cost for these agents. The current ceiling price for carboplatin in India stands at ₹61.10 per 10 mg/mL vial, while cisplatin ranges from ₹70 to ₹300 depending on strength. With platinum prices surging due to supply constraints from South Africa and Russia — the two dominant producers — these ceilings no longer cover manufacturing costs.
Companies including Cipla, Intas, Dr Reddy's, Zydus Lifesciences, and Emcure have collectively warned that without price revisions, supply of these backbone chemotherapy agents could be at risk globally.
The WHO has flagged 2026 as the worst year for oncology drug shortages since 2019, with shortages persisting months longer than pre-pandemic norms.
Dual sourcing becomes critical: Pharma companies relying on single-source platinum API supply face unacceptable risk. Suppliers with validated synthesis capabilities and existing regulatory filings stand to gain significant new business.
Vertical integration advantages: CDMOs that secure platinum feedstock through long-term supply agreements offer customers more stable pricing — a key differentiator when raw material volatility is the primary disruptor.
Geographic diversification: The concentration of API manufacturing in India and China creates systemic risk. FDA's PreCheck Pilot Program signals growing policy interest in diversifying essential drug supply chains.
Clinical studies link drug shortages to 10–20% survival drops in ovarian and lung cancers. Hospitals are forced to ration doses, delay treatment, or substitute less effective alternatives. ASCO warns that carboplatin shortages risk undoing decades of progress in ovarian cancer treatment.
The platinum oncology drug shortage is unlikely to resolve quickly. Until regulatory price ceilings adjust or diversified API supply chains mature, oncology drug supply will remain fragile. For API manufacturers with platinum-complex capabilities, this crisis represents both a responsibility and an opportunity: to stabilize supply while building more resilient manufacturing networks for the future.
